Apogee Therapeutics (NASDAQ:APGE) Now Covered by Citigroup

Citigroup began coverage on shares of Apogee Therapeutics (NASDAQ:APGE) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $95.00 target price on the stock.

A number of other brokerages have also recently issued reports on APGE. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $92.17.

Apogee Therapeutics Stock Down 0.5 %

NASDAQ:APGE opened at $38.33 on Thursday. Apogee Therapeutics has a twelve month low of $29.10 and a twelve month high of $71.75. The business has a 50 day moving average price of $38.55 and a two-hundred day moving average price of $46.71. The company has a market cap of $1.73 billion, a P/E ratio of -15.84 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). As a group, analysts anticipate that Apogee Therapeutics will post -3.09 earnings per share for the current fiscal year.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $48.85, for a total transaction of $732,750.00. Following the transaction, the chief executive officer now owns 1,309,487 shares in the company, valued at $63,968,439.95. This trade represents a 1.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Carl Dambkowski sold 3,520 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total value of $143,228.80. Following the transaction, the insider now owns 252,623 shares in the company, valued at $10,279,229.87. The trade was a 1.37 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,195 shares of company stock worth $2,026,392. Company insiders own 36.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in APGE. GF Fund Management CO. LTD. bought a new position in Apogee Therapeutics during the 4th quarter worth $43,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Apogee Therapeutics during the 3rd quarter worth $71,000. Optimize Financial Inc bought a new position in Apogee Therapeutics during the 4th quarter worth $203,000. Aigen Investment Management LP acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth $216,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth $219,000. Institutional investors own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.